Join us as we go over our top stories from the week:
Google is Reportedly Gathering Health Data on Millions of Americans.
EIP Pharma Announces Mixed Results from Phase 2b REVERSE-SD Study of Neflamapimod in Early-stage Alzheimer’s Disease.
Clinical Investigation Site Summary: Josephson, Wallack, Munshower Neurology PC Treating Alzheimer’s Disease.
Pfizer/Merck’s Bavencio Fails to Meet Primary Objective in Phase III JAVELIN Gastric 100 Study.
Raising Public Awareness for Lung Cancer Clinical Trials: LUNGevity Launches Campaigns to Help Save Lives.
University of Florence & ICR London Discover Change in Cell Logistics Helps Breast Cancer to Become Resistant to Hormone Therapy.
Dr. Patrick Sung, PhD back at University of Texas Health Science Center & Attracts $20.9m for Cancer Research.
ASLAN Pharma’s Pivotal TREETOPP Study of Varlitinib in Biliary Tract Cancer Fails to Reach Endpoint.
Apple Research Apps Represents Compelling Potential to Transform Health Research.
More Private Equity Moving into Clinical Trials Services Showcasing the Importance and Value of the Industry.
Intermountain Healthcare Study Reveals Statin Adherence Requires a Simple Digital ‘Nudge’.
Trending Topics at FDA as Presented at the 2019 Utah Life Sciences Summit.
Why we Need Diversity in Clinical Trials Research: An Interview with Linda Lopez-George of UT Health San Antonio.
Clinical Research as Care Option Expands as Javara Inks Partnership with Privia Health.
Moleculin Announces FDA Approval of IND for WP1066 in Emory University Clinical Trial.
Kiadis Announces Restructuring, Development of Lead T-cell Asset ATIR101 Discontinued to Focus on NK-Cell Platform.
Genentech Reports Data from SUNFISH Trial of Risdiplam in Patients with Type 2 or 3 Spinal Muscular Atrophy.
Can Zinc Gluconate Help Reduce Intensity of Hidradenitis Suppurativa?
Does a Non-Opioid Pain Medication Work? A Current Bunion Surgery Clinical Trial May Provide Some Answers.
UConn & UNC at Chapel Hill Research Team Launch Drug Therapy Venture at UConn’s Technology Incubation Program.
Cohen Veterans Bioscience & Parexel’s New Emerging Biopharma Unit Ink Landmark Adaptive Clinical Program Targeting PTSD.
Clinical Trials 04:51